Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ZIVO Bioscience, Inc. ZIVO OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
39/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$12.00
+438.6%

ZIVO Bioscience, Inc. (ZIVO) is a Biotechnology company in the Healthcare sector, currently trading at $2.23. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is ZIVO = $12 (+438.6% upside).

Financials: revenue is $157,220, +468.6%/yr average growth. Net income is $13M (loss), growing at -18%/yr. Net profit margin is -8513.4% (negative). Gross margin is 31.1% (-10.9 pp trend).

Balance sheet: total debt is $254,361 against $2M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 0.8 (tight liquidity). Debt-to-assets is 15.5%. Total assets: $2M.

Analyst outlook: 0 / 1 analysts rate ZIVO as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 21/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$12.00
▲ 438.6% Upside
Average Price Target
The 12-month price target for ZIVO Bioscience, Inc. is $12.00.

ZIVO SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ZIVO

✓
VALUE Pass
100/100
ZIVO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $12, implying +438.6% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ZIVO: +468.6%/yr revenue is, -18%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet ZIVO: Debt-to-Equity (D/E) ratio 0.17 (conservative), Current ratio is 0.8 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
ZIVO: Gross margin is 31.1% (-10.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 0 / 1 analysts rate ZIVO as buy (0%). Analyst consensus target is $12 (+438.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ZIVO: Net profit margin is -8513.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.14-20
Volume6.93K
Avg Volume (30D)2.62K
Market Cap$8.66M
Beta (1Y)0.51
Share Statistics
EPS (TTM)-3.92
Shares Outstanding$3.41M
IPO Date2003-12-15
Employees7
CEOJohn Bernard Payne
Financial Highlights & Ratios
Revenue (TTM)$157.22K
Gross Profit$48.95K
EBITDA$-13.36M
Net Income$-13.38M
Operating Income$-13.36M
Total Cash$1.54M
Total Debt$254.36K
Net Debt$-1.29M
Total Assets$1.64M
Price / Earnings (P/E)-0.6
Price / Sales (P/S)55.11
Analyst Forecast
1Y Price Target$12.00
Target High$12.00
Target Low$12.00
Upside+438.6%
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS98978N3098

Price Chart

Track all markets on TradingView
ZIVO
ZIVO Bioscience, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
3.14 52WK RANGE 20.00

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.95
+2.20%
 FBRX
FBRX
Forte Biosciences, Inc.
$31.28
-3.52%
 FHTX
FHTX
Foghorn Therapeutics Inc.
$4.87
+0.41%
 THRX
THRX
Theseus Pharmaceuticals, Inc.
$4.07
+0.12%
 RNXT
RNXT
RenovoRx, Inc.
$1.02
-0.97%
 ABIO
ABIO
ARCA biopharma, Inc.
$28.80
+1,052.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message